Skip to main content

Advertisement

Table 3 Hospital resource use up to 6 months for trial participants

From: Cost-effectiveness of a cardiac output-guided haemodynamic therapy algorithm in high-risk patients undergoing major gastrointestinal surgery

  Peri-operative cardiac output-guided, haemodynamic therapy algorithm Usual care
(n = 368) (n = 365)
Surgery   
 Upper gastrointestinal 108 (29.4) 111 (30.4)
 Lower gastrointestinal 168 (45.7) 165 (45.2)
 Small bowel +/− pancreas 86 (23.4) 82 (22.5)
 Urological or gynaecological involving gut 5 (1.4) 4 (1.1)
 No surgery performed 1 (0.3) 3 (0.8)
Intervention   
 Cardiac monitor used 364 (98.9) 31 (8.5)
 Dopexamine dose infused (mg) 18.9 (8.4)
 Intra-venous crystalloid (ml)   
  During surgery 1518 (1410) 2420 (1382)
  6 h following surgery 565 (254) 670 (367)
 Intra-venous colloid (ml)   
  During surgery 1465 (913) 708 (695)
  6 h following surgery 642 (498) 226 (361)
 Blood products (ml)   
  During surgery 141 (723) 95 (542)
  6 h following surgery 80 (555) 10 (66)
Length of stay (days)   
 Critical care level 2 2.5 (3.7) 2.6 (3.4)
 Critical care level 3 0.7 (2.4) 0.9 (3.8)
 General surgical ward 10.3 (14.4) 11.4 (12.6)
  1. Data presented as mean (SD) or n (%)